RxDoctor Payments Data

Rojina Pant, MD

Cardiovascular Disease · Greensboro, NCNPI 1336454040

Payments from drug & device makers

$2,361in general payments, 2019–2025

Across 96 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$522
  • Edwards Lifesciences$295
  • E.r. Squibb & Sons, L.L.C.$250
  • Boston Scientific$232
  • Heartflow, Inc.$187
  • Pfizer$124
  • plus $751 from 18 others

What the payments were for

  • Consulting fees$131%
  • Food & beverage$2,33499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,361 in reported general payments places this provider in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$246,179
Medicare patients
1,346
Services billed
2,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban269$324,347
EntrestoSacubitril/Valsartan124$127,968
XareltoRivaroxaban51$63,073
JardianceEmpagliflozin33$30,401
Repatha SureclickEvolocumab37$25,099
FarxigaDapagliflozin Propanediol12$11,429
Metoprolol Succinate424$5,471
Flecainide Acetate55$2,891
Rosuvastatin Calcium200$2,840
Amiodarone Hcl53$2,695
Atorvastatin Calcium184$1,950
Losartan Potassium200$1,626
Diltiazem 24hr Er (Cd)Diltiazem Hcl79$1,509
Potassium Chloride118$1,418
Carvedilol116$1,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$324,347269 claims
NovartisEntresto$522$127,968124 claims
Johnson & JohnsonXarelto$120$63,07351 claims
Boehringer IngelheimJardiance$18$30,40133 claims
AstraZenecaFarxiga$112$11,42912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →